Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year
In the leadup to a “major expected” Phase III trial readout for asciminib in third-line chronic myelogenous leukemia, Novartis has unceremoniously removed a planned filing for the same drug as an earlier line of therapy — which is still being tested in Phase II.
The Swiss pharma giant gave the update on asciminib, also dubbed ABL001, exactly one line in its 160-page presentation on Q4 and FY 2019 results, alongside a disclosure that it’s dropped a Phase III for Ilaris (canakinumab) in hereditary periodic fevers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
